Genmab — December 2021
-
Mandagens aktier: Novo i kursderoute - C25 rettede op https://www.proinvestor.com/investornyt/751909/mandagens-aktier-novo-i-kursderoute-c25-rettede-op
-
God morgen.
-
Asian Markets Trading Mostly Higher
https://www.proinvestor.com/investornyt/752246/asian-markets-trading-mostly-higher -
Investorerne er på tilbudsjagt efter mandagens nedtur https://www.proinvestor.com/investornyt/752256/asien-investorerne-er-pa-tilbudsjagt-efter-mandagens-nedtur
-
Tirsdagens aviser med Novo Nordisk,
Carlsberg og Danica https://www.proinvestor.com/investornyt/752258/tirsdagens-aviser-med-novo-nordisk-carlsberg-og-danica -
European Shares Set To Follow Asian Peers Higher https://www.proinvestor.com/investornyt/752259/european-shares-set-to-follow-asian-peers-higher
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/99606_Skaermbillede_2021_12_21_143417_rykker.jpg
Så er der et stærkt købs signal på 68% -
Aktier/tendens: Muligt comeback efter rød mandag https://www.proinvestor.com
/investornyt/752283/aktier-tendens-muligt-comeback-efter-rod-mandag -
NMPA China announced today that
@Novartis
has obtained BLA approval for its anti-CD20 antibody ofatumumab injection to be used in adult patients with refractory multiple sclerosis (RMS) https://twitter.com/pharmcube/status/1473126993999073282 -
De dukker som regel op i løbet af formiddagen. Det gør de nok også i morgen.
-
God morgen.
-
Asien: Let positive markeder med svag omsætning https://www.proinvestor.com/investornyt/752906/asien-let-positive-markeder-med-svag-omsaetning
-
Onsdagens aviser med Danske Bank, Aarsleff og Velux
https://www.proinvestor.com/investornyt/752905/onsdagens-aviser-med-danske-bank-aarsleff-og-velux -
TA investerings case stadig intakt. Som det ses på kortet tog det kun 2 dage fra ca. 2750 til 2500 så det bliver spændende, at se kommende handelsdage hvor meget modstand der er i området op til de 2750 eller højere https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/99621_Skaermbillede_2021_12_22_140540_intakt.jpg
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-021-00343-3
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind